MIRA Pharmaceuticals, Inc. (MIRA)

NASDAQ: MIRA · Real-Time Price · USD

1.100

-0.010 (-0.90%)

At close: Feb 21, 2025, 4:00 PM

1.120

+0.020 (1.82%)

After-hours: Feb 21, 2025, 7:38 PM EST

MIRA Pharmaceuticals Employees

The last reported number of employees for MIRA Pharmaceuticals was 3.

Employees

3

Change

n/a

Growth

n/a

Revenue / Employee

n/a

Profits / Employee

-$3,746,780

Market Cap

18.22M

No historical employees data available.

Related Stocks

Company Name	Employees
UnitedHealth Group	440,000
Johnson & Johnson	131,900
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	72,000

Employee Rankings

MIRA News

2 months ago - MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - Accesswire
2 months ago - MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End - Accesswire
3 months ago - MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site - Accesswire
4 months ago - MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain - Accesswire
4 months ago - MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study - Accesswire
5 months ago - MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024 - Accesswire
5 months ago - MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025 - Accesswire
5 months ago - MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Accesswire